This is a preview of subscription content, log in via an institution to check access.
Notes
epidermal growth factor receptor
Drug prices were taken from the Drug Bidding Information Inquiry; other costs were estimated from published literature. A 5% annual discount rate was used.
The WTP threshold was 3 times the gross domestic product of China.
Reference
Luo S, et al. Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis. International Journal of Clinical Pharmacy : 11 Oct 2021. Available from: URL: http://doi.org/10.1007/s11096-021-01333-z
Rights and permissions
About this article
Cite this article
For NSCLC with leptomeningeal metastases in China, osimertinib cost effective - with caveats. PharmacoEcon Outcomes News 890, 8 (2021). https://doi.org/10.1007/s40274-021-08131-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08131-z